Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of 3BNC117 in HIV-infected and Uninfected Volunteers
NCT02018510Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- Jan 2014
- Primary completion
- Jan 2016
- Modality
- Anti-infectious Disease mAbs
- Countries
- 2
01
Overview
Phase 1, open-label trial of Teropavimab in human immunodeficiency virus infection (HIV) (15 arms), sponsored by The Rockefeller University. Primary endpoint: Safety and tolerability at 24 weeks. Started Jan 2014; status: completed.
02
Drugs
Teropavimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02018510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02018510.